Physician profile
Eric M Rosenbaum
NPI 1447662762
$3,729.10
in general payments reported to CMS, 2019-2025
36 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $314 · 2021: $659 · 2022: $508 · 2023: $491 · 2024: $436 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $470.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $416.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $373.88 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $351.51 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $287.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $272.14 | 2019-2025 | Repatha, Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $250.60 | 2019-2022 | |
| Abbvie INC. | $138.83 | 2021-2025 | Vraylar |
| Abbott Laboratories | $127.95 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.20 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $96.43 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $88.86 | 2019-2023 | |
| Indivior INC. | $72.42 | 2021-2024 | Sublocade |
| Astellas Pharma US INC | $71.49 | 2019-2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $67.40 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $59.47 | 2021-2022 | |
| Exact Sciences Corporation | $50.46 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $44.98 | 2019-2023 | Xarelto |
| Horizon Therapeutics Plc | $43.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $43.18 | 2022-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $34.13 | 2021 | |
| Allergan, INC. | $26.36 | 2019 | |
| Sumitomo Pharma America, INC. | $22.30 | 2025 | Gemtesa |
| Dexcom, INC. | $22.07 | 2024 | Dexcom G6 Transmitter |
| Axonics, INC. | $19.67 | 2021 | |
| Genentech USA, INC. | $19.08 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.12 | 2024 | Crysvita |
| Ironshore Pharmaceuticals INC. | $16.81 | 2019 | |
| Irhythm Technologies, INC. | $16.52 | 2022 | |
| Amarin Pharma, INC. | $16.27 | 2019 | |
| Janssen Biotech, INC. | $14.49 | 2019 | |
| Grifols USA, LLC | $14.00 | 2019 | |
| Eisai INC. | $13.26 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.97 | 2021 | |
| Daiichi Sankyo INC. | $12.71 | 2020 | |
| Nestle Healthcare Nutrition INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Rosenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.